Noritren (Nortriptyline Hydrochloride)

Nortriptyline, the active ingredient in Noritren, is a tricyclic antidepressant presented as an oral dosage form for systemic use. It is prescribed through clinical assessment for major depressive disorder, neuropathic pain, and certain anxiety disorders in adult patients worldwide.

GNH USA supplies Noritren as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for importers. Its global logistics network ensures timely delivery across Europe, Asia, Africa and the Americas.

Nortriptyline is a tricyclic antidepressant that acts on mood and pain pathways.

- Major depressive disorder: alleviates depressive symptoms, improves mood, and enhances functional capacity in adults. - Neuropathic pain: reduces pain intensity and abnormal sensory sensations caused by peripheral nerve damage, improving quality of life. - Anxiety disorders: helps control excessive worry, physiological anxiety signs, and associated sleep disturbances.

Nortriptyline may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dry mouth - Constipation - Drowsiness or sedation - Blurred vision

Serious or Rare Side Effects: - Cardiac arrhythmias - Seizures - Severe hypotension - Agranulocytosis

When prescribing Noritren, clinicians should consider several safety factors. - Cardiac conditions: assess ECG and avoid use in patients with recent myocardial infarction. - Seizure risk: use cautiously in individuals with a history of seizures. - Glaucoma: monitor intra‑ocular pressure as anticholinergic effects may exacerbate the condition. - Elderly patients: start at low dose and monitor for falls and confusion. - Drug interactions: review concomitant medications that affect CYP2D6 metabolism. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture.

Nortriptyline interacts with several drug classes; awareness of the interaction severity guides clinical decisions.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis; must be discontinued at least 14 days prior. - SSRIs or SNRIs: increased risk of serotonin syndrome. - Anticholinergic drugs: additive anticholinergic burden. - Certain antiarrhythmics (e.g., quinidine): can cause serious cardiac effects.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise nortriptyline levels. - CNS depressants (e.g., alcohol, benzodiazepines): enhance sedation. - Diuretics: may potentiate orthostatic hypotension.